NEJM March 12 2026 Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

This clinical study investigates the safety profiles of two common blood thinners by comparing their potential to cause harmful side effects during the treatment of blood clots. Researchers conducted a large-scale international trial to determine whether patients using apixaban or rivaroxaban faced a higher danger of clinically relevant bleeding over a three-month period. The findings revealed that those treated with apixaban experienced significantly lower bleeding risks, with less than half the incident rate of the rivaroxaban group. Ultimately, the trial provides critical evidence that apixaban serves as a safer anticoagulation alternative for individuals managing acute venous thromboembolism.